Evaluation of Combination DNA/Replication-Competent Ad-SIV Recombinant Immunization Regimens in Rhesus Macaques

AIDS Research and Human Retroviruses

Volumn 20, Issue 2, 2004, Pages 235-244

  Malkevitch, Nina ^a   Rohne, Daniela ^b   Pinczewski, Joel ^a   Aldrich, Kristine ^a   Kalyanaraman, V S ^c   Letvin, Norman L ^b   Robert Guroff, Marjorie ^a,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN GP 120; RECOMBINANT DNA; RECOMBINANT VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS VECTOR;

ANTIGEN BINDING; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA REPLICATION; ENVELOPE GENE; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LYSIS; MALE; MONKEY DISEASE; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; REVIEW; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; TARGET CELL; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENETIC VECTORS; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; INTERFERON TYPE II; MACACA MULATTA; MALE; MEMBRANE GLYCOPROTEINS; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

EID: 1442274708     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922204773004969     Document Type: Review

References (53)

1. Mazzoli S, Trabattoni D, Lo Caputo S, Piconi S, Ble C, Meacci F, Ruzzante S, Slavi A, Semplici F, Longhi R, Fusi ML, Tofani N, Biasin M, Villa ML, Mazzotta F, and Clerici M: HIV-1-specific mucosal and cellular immunity in HIV-1-seronegative partners of HIV-1-seropositive individuals. Nat Med 1997;3:1250-1257.
2. Rowland-Jones S, Sutton J, Arioshy K, Dong T, Gotch F, McAdam S, Whitby D, Sabally S, Gallimore A, Corrah T, Takiguchi M, Schultz T, McMichael A, and Whittle H: HIV-1-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995;1:59-64.
3. Kent S, Woodward A, and Zhao A: Human immunodeficiency virus type 1 (HIV-1)-specific T cell responses correlate with control of acute HIV-1 infection in macaques. J Infect Dis 1997;176: 1188-1197.
4. Koup R, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, and Ho DD: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68: 4650-4655.
5. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, and Walker BD: Vigorous HIV-1 specific CD4+ T cell responses associated with control of viremia. Science 1997;278:1447-1450.
6. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, Bacz P, Tenner-Racz K, Dalesandro M, Scallon BJ, Ghrayeb J, Forman MA, Montefiori DC, Rieber EP, Letvin NL, and Reimann KA: Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999;283:857-860.
7. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, Irwin CE, Safrit JT, Mittler J, Weinberger I, Kostrikis LG, Zhang L, Perelson AS, and Ho DD: Dramatic rise in plasma viremia after CD8+ T cell depletion in SIV-infected macaques. J Exp Med 1999;189:991-998.
8. Kuroda MJ, Schmidt JE, Charini WA, Nickerson CE, Lifton MA, Lord CI, Forman MA, and Letvin NL: Energence of CTL coincides with clearance of virus during primary SIV infection in rhesus monkeys. J Immunol 1999;162:5127-5133.
9. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, Louder MK, Brown CR, Sapan CV, Frankel SS, Lu Y, Robb ML, Katinger H, and Birx DL: Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999;73:4009-4018.
10. Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, Willey R, Cho MW, and Martin M: Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. N Med 1999;5:204-210.
11. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, and Lewis MG: Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000;6:207-210.
12. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, Cavacini LA, Posner MR, Katinger H, Stieglar G, Barnacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Lu J, Wright JE, Chou TC, and Ruprecht RM: Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian/human immunodeficiency virus infection. Nat Med 2000;6:200-206.
13. Van Rompay KK, Berardi CJ, Dillard-Telm S, Tarara RP, Canfield DR, Valverde CR, Montefiori DC, Cole KS, Montelaro RC, Miller CJ, and Marthas ML: Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J Infect Dis 1998;177:1247-1259.
14. Muthumani K, Kudchodkar S, Zhang D, Bagarazzi ML, Kim JJ, Boyer JD, Ayyavoo V, Pavlakis GN, and Weiner BB: Issues for improving multiplasmid DNA vaccines for HIV-1. Vaccine 2002; 20:1999-2003.
15. Tang DC, De Vit M, and Johnson SA: Genetic immunization is a simple method for eliciting an immune response. Nature 1992;356: 152-154.
16. Barouch DH, Craiu A, Kuroda MJ, Schmitz JE, Zheng XX, Santra S, Frost JD, Krivulka GR, Lifton MA, Crabbs CL, Heidecker G, Perry HC, Davies M, Xie H, Nickerson CE, Steenbeke TD, Lord CI, Montefiori DC, Strom TB, Shiver JW, Lewis MG, and Letvin NL: Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci USA 2000;97: 4192-4197.
17. Biragyn A, Belyakov IM, Chow Y-H, Dimitrov DS, Berzofsky JA, and Kwak LW: DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood 2002;100:1153-1159.
18. Sailaja G, Husain S, Nayak BP, and Jabbar AM: Long-term maintenance of gp120-specific immune responses by genetic vaccination with the HIV-1 envelope genes linked to the gene encoding Flt-3 ligand. J Immunol 2003;170:2496-2507.
19. Green TD, Montefiori DC, and Ross TM: Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J Virol 2003;77:2046-2055.
20. Kojima Y, Xin K-Q, Ooki T, Hamajima K, Oikawa T, Shinoda K, Ozaki T, Hoshino Y, Jounai N, Nakazawa M, Klinman D, and Okuda K: Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine. Vaccine 2002;20:2857-2865.
21. Caputo A, Gavioli R, Altavilla G, Brocca-Cofano E, Boarini C, Betti M, Castaldello A, Lorenzini F, Micheletti F, Cafaro A, Sparnacci K, Laus M, Tondelli L, and Ensoli B: Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat. Vaccine 2003;21: 1103-1111.
22. Voltan R and Robert-Guroff M: Live recombinant vectors for AIDS vaccine development. Curr Mol Med 2003;3:273-284.
23. Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, Becker M, Sinden R, Smith GL, and Hill AVS: Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998;4:397-402.
24. Hanke T, Samuel RV, Blanchard TJ, Neumann VC, Allen TM, Boyson JE, Sharpe SA, Cook N, Smith GL, Watkins DI, Cranage MP, and McMichael AJ: Effective induction in simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 1999;73:7524-7532.
25. Allen TM, Vogel TU, Fuller DH, Mothe BR, Steffen S, Boyson JE, Shipley T, Fuller J, Hanke T, Sette A, Altman JD, Moss B, McMichael AJ, and Watkins DI: Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol 2000;164:4968-4978.
26. Robinson HL, Montefiori DC, Johnson RP, Manson KH, Kalish ML, Lifson JD, Rizvi TA, Lu S, Hu S-L, Mazzara GP, Panicali DL, Herndon JG, Glickman R, Candido MA, Lydy SL, Wyand MW, and McClure HM: Neutralizing antibody- independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 1999;5:526-534.
27. Hel Z, Tsai WP, Thornton A, Nacsa J, Giuliani L, Tryniszewska E, Poudyal M, Venzon D, Wang X, Altman J, Watkins DI, Lu W, von Gegerfelt A, Felber BK, Tartaglia J, Pavlakis GN, and Franchini G: Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. J Immunol 2001;167:7180-7191.
28. Xiang ZQ, Pasquini S, and Ertl HCJ: Induction of genital immunity by DNA priming and intranasal booster immunization with a replication-defective adenoviral recombinant. J Immunol 1999; 162:6716-6723.
29. Vinner L, Wee EG-T, Patel S, Corbet S, Gao GP, Nielsen C, Wilson JM, Ertl HC, Hanke T, and Fomsgaard A: Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost. J Gen Virol 2003;84:203-213.
30. Matano T, Kano M, Nakamura H, Takeda A, and Nagai Y: Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen. J Virol 2001;75:11891-11896.
31. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, Candido MA, Kozyr NL, Earl PL, Smith JM, Ma H-L, Grimm BD, Hulsey ML, Miller J, McClure HM, McNicholl JM, Moss B, and Robinson HL: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001;292:69-74.
32. Hel Z, Nacsa J, Tryniszewska E, Tsai WP, Parks RW, Montefiori DC, Felber BK, Tartaglia J, Pavlakis GN, and Franchini G: Containment of simian immunodeficiency virus infection in vaccinated macaques: Correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. J Immunol 2002;169:4778-4787.
33. Shiver JW, Fu TW, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Mach H, Troutman RD, Isopl LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Mirua A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caufeld MJ, Bett AJ, Youil R, Kaslow DC, and Emini EA: Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency virus immunity. Nature 2002;415:331-335.
34. Lubeck MD, Natuk RJ, Myagkikh M, Kalyan N, Aldrich K, Sinangil F, Alipanah S, Murty L, Chanda PK, Nigida SM, Markham PD, Zolla-Pazner S, Steimer K, Wade M, Reitz MS Jr, Arthur LO, Mizutani S, Davis A, Hung PP, Gallo RC, Eichberg J, and Robert-Guroff M: Long-term protection of chimpanzees against high dose HIV-1 challenge induced by immunization. Nat Med 1997;3: 651-658.
35. Robert-Guroff M, Kaur H, Patterson LJ, Leno M, Conley AJ, McKenna PM, Markham PD, Richardson E, Aldrich K, Murty L, Carter L, Zolla-Pazner S, and Sinangil F: Vaccine protection against a heterologous non-sycytium-inducing, primary human immunodeficiency virus. J Virol 1998;72:10275-10280.
36. Zolla-Pazner S, Lubeck M, Xu S, Burda S, Natuk RJ, Sinangil K, Steimer K, Gallo RC, Eichberg JW, Matthews T, and Robert-Guroff M: Induction of neutralizing antibodies in chimpanzees to T-cell line adapted and primary HIV-1 isolates with a prime/boost vaccine regimen in chimpanzees. J Virol 1998;72: 1052-1059.
37. Buge SL, Richardson E, Alipanah S, Markham P, Cheng S, Kalyan N, Miller CJ, Lubeck M, Udem S, Eldridge J, and Robert-Guroff M: An adenovirus-SIV env vaccine elicits humoral, cellular and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J Virol 1997;71:8531-8541.
38. Buge SL, Murty L, Arora K, Kalyanaraman VS, Markham PD, Richardson ES, Aldrich K, Patterson LJ, Miller CJ, Cheng S, and Robert-Guroff M: Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251. J Virol 1999;72:7430-7440. (Erratum: J Virol 1999;73:9692.)
39. Patterson LJ, Robey F, Muck A, Van Remoortere K, Aldrich K, Richardson E, Alvord WG, Markham PD, Cranage M, and Robert-Guroff MA: A conformational C4 peptide polymer vaccine coupled with live recombinant vector priming is immunogenic but does not protect against rectal SIV challenge. AIDS Res Hum Retroviruses 2001;17:837-849.
40. Patterson LJ, Malkevitch N, Zhao J, Peng B, and Robert-Guroff M: Potent, persistent cellular immune responses elicited by sequential immunization of rhesus macaques with Ad5 host range mutant recombinants encoding SIV Rev and SIV Nef. DNA Cell Biol 2002;21:627-635.
41. Malkevitch N, Patterson LJ, Aldrich K, Richardson E, Alvord WG, and Robert-Guroff M: A replication competent Ad5hr-SIV recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Maimi-A*-1 rhesus macaques. J Immunol 2003;170:4281-4289.
42. Patterson LJ, Malkevitch N, Pinczewski J, Venzon D, Lou Y, Peng B, Munch C, Leonard M, Richardson E, Aldrich K, Kalyanaraman VS, Pavlakis GN, and Robert-Guroff M: Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIVgp120. J Virol 2003;77:8607-8620.
43. Zhao J, Lou Y, Pinczewski J, Maklevitch N, Aldrich K, Kalyanaraman VS, Venzon D, Peng B, Patterson LJ, Edghill-Smith Y, Woodward R, Pavlakis GN, and Robert-Guroff M: Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIV env/rev and Ad5hr-SIV gag recombinants. Vaccine 2003;21:4022-4035.
44. mac251 challenge by a replication competent Ad5hr-SIV env/rev and Ad5hr-SIV gag recombinant priming/gp120 boosting regimen. J Virol 2003;77:8354-8365.
45. Patterson LJ, Malkevitch N, Venzon D, Pinczewski J, Gomez-Roman VR, Wang L, Kalyanaraman VS, Markham PD, Robey FA, and Robert-Guroff M: Protection against mucosal SIVmac251 challenge using replicating adenovirus-SIV multi-gene vaccine priming and subunit boosting. J Virol 2004 (in press).
46. Cheng SM, Lee SG, Ronchetti-Blume M, Virk KP, Mizutani S, Eichberg JW, Davis A, Hung PP, Hirsch VM, Chanock RM, Purcell RH, and Johnson PR: Coexpression of the simian immunodeficiency virus Env and Rev proteins by a recombinant human adenovirus host range mutant. J Virol 1992;66:6721-6727.
47. Karasuyama H, Tohyama N, and Tada T: Autocrine growth and tumorigenicity of interleukin 2-dependent helper T cells transfected with IL-2 gene. J Exp Med 1989;169:13-25.
48. Hirsch VM, Olmsted RA, Murphey-Corb M, Purcell RH, and Johnson PR: An African primate lentivirus (SIVsm) closely related to HIV-2. Nature 1989;339:389-392.
49. Kalyanaraman VS, Rodrigueq V, Veronese F, Rahman R, Lusso P, DeVico AL, Copeland T, Oroszlan S, Gallo RC, and Sarngadharan MG: Characterization of the secreted, native gp120 and gp160 of the human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1990;6:371-380.
50. Hirsch VM, Fuerst TR, Sulter G, Carroll MW, Yang LC, Goldstein S, Piatak M Jr, Elkins WR, Alvord WG, Montefiori DC, Moss B, and Lifson JD: Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol 1996;70:3741-3752.
51. Fuller DH, Simpson L, Cole KS, Clements JE, Panicali DL, Montelaro RC, Murphey-Corb M, and Haynes JR: Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV. Immunol Cell Biol 1997;75: 389-396.
52. Horton H, Vogel TU, Carter DK, Vielhuber K, Fuller DH, Shipley T, Fuller JT, Kunstman KJ, Sutter G, Montefiori DC, Erfle V, Desrosiers RC, Wilson N, Picker LJ, Wolinsky SM, Wang C, Allison DB, and Watkins DI: Immunization of rhesus macaques with a DNA primed/modified vaccinia Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIV-mac239. J Virol 2002;76:7187-7202.
53. Casimiro DR, Chen L, Fu T-M, Evans RK, Caulfield MJ, Davies M-E, Tang A, Chen M, Huang L, Harris V, Freed DC, Wilson KA, Dubey S, Zhu D-M, Nawrocki D, Mach H, Troutman R, Isopi L, Williams D, Hurni W, Xu Z, Smith JG, Wang S, Liu X, Guan L, Long R, Trigona W, Heidecker GJ, Perry HC, Persaud N, Toner TJ, Su Q, Liang X, Youil R, Chastain M, Bett AJ, Volkin DB, Emini EA, and Shiver JW: Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003;77:6305-6313.